Biota Holdings Limited

 ASX:BTA ISIN:AU000000BTA1

Feb 11, 2012

 

OVERVIEW  | NEWS  | MULTIMEDIA  | RESEARCH

News Reader RSS   Biota Holdings Limited
 
 Biota Holdings Limited (ASX:BTA) Revised Relenza Royalty For December 2008 Quarter
FEB 13, 2009 11:45 - Article Views: 2,770
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today reported that it had received revised advice from GlaxoSmithKline (GSK) regarding Relenza sales for the December 2008 quarter. The revised sales were A$27.1 million (US$20.8 million) and indicative royalties were A$1.9 million (US$1.46 million).
 Biota Holdings Limited (ASX:BTA) GSK Imports Additional Relenza To Japan
FEB 11, 2009 10:27 - Article Views: 3,302
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that GlaxoSmithKline (GSK) has advised of the current Relenza supply situation in respect to the key market of Japan.
 Biota Holdings Limited (ASX:BTA) Relenza Royalty For December 2008 Quarter
FEB 6, 2009 10:04 - Article Views: 2,683
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that it had received written notification from GlaxoSmithKline (GSK) that Relenza sales were $20.8 million and indicative royalties were $1.46 million, for the three months ended 31 December 2008.
 Australian Market Report of January 30: Ending Three-Day Rally
JAN 30, 2009 13:00 - Article Views: 7,232
On Thursday, the Australian shares rose for the third consecutive day led by rallies in overseas markets and strong commodities prices. The benchmark S&P/ASX200 index was up 30.7 points, or 0.88 per cent, at 3,526.2, while the broader All Ordinaries index had gained 26.2 points, or 0.76 per cent, to 3,461.3. The Australian market might lose its recent gains following the heavy fall in Wall St.
 Biota Holdings Limited (ASX:BTA) UK GOVERNMENT ORDERS 10.6 MILLION COURSES OF RELENZA
JAN 30, 2009 10:41 - Article Views: 2,382
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that GlaxoSmithKline (GSK) has been awarded a significant contract by the UK Department of Health for 10.6 million treatment courses of RelenzaTM (zanamivir).
 Biota Holdings Limited (ASX:BTA) Appoints Mr Richard Hill As Director
NOV 28, 2008 15:50 - Article Views: 3,723
Biota Holdings Limited (ASX:BTA)(PNK:BTAHY) announced today the appointment of Mr Richard Hill as a non executive Director.
 Biota Holdings Limited (ASX:BTA) LANI Phase III Clinical Trials Set For Enrolment
NOV 17, 2008 12:02 - Article Views: 5,067
Biota Holdings Limited (ASX:BTA)(PNK:BTAHY) today announced that the multiple centres involved in the Phase III clinical trail on its long acting neuraminidase inhibitor (LANI) CS-8958 are ready to commence treatment. Patients are expected to enrol into the study progressively throughout the Asian influenza season.
 Biota Holdings Limited (ASX:BTA) Relenza Q1 Royalty Of $1.9M On Sales of $27.1M
OCT 23, 2008 10:36 - Article Views: 1,382
Biota Holdings Limited (ASX:BTA)(PNK:BTAHY) today announced that it had received written notification from GlaxoSmithKline (GSK) that Relenza sales were $27.1 million and indicative royalties were $1.9 million, for the three months ended 30 September 2008.
 Biota Holdings Limited (ASX:BTA) RSV Licence Assigned to Astrazeneca And Territories Expanded
AUG 25, 2008 11:16 - Article Views: 2,040
Biota Holdings Limited (ASX:BTA) and AstraZeneca (LON:AZN) today announced that the 2005 Collaboration and License Agreement with MedImmune has been assigned to AstraZeneca. AstraZeneca has also secured the rights to a number of Asian and Pacific territories not held by MedImmune under the original agreement and for which Biota will receive an additional US$3.5 million payment, plus future royalties.
More Articles:
 

View in Other Languages

      

Site Search

 
    All Languages
Team Trev Zero Race 2010

ABN Newswire on iPhone/iPad

Download from Apple

Mobile Video TV

qrcode
Scan with your Mobile Phone to view ABN Newswire Video Channel on Mobile
 
City Index - A Better Way To Trade

209,672 Article Views In All Supported Languages

 

RESEARCH